Supplementary Figure S14 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Abstract
MS-553 inhibits downstream BCR and Wnt/β-catenin signaling in BTKi resistant CLL.
Fields of Study & Subjects
Chronic Lymphocytic Leukemia Research
Lymphoma Diagnosis and Treatment
Acute Lymphoblastic Leukemia research
Publication details
- Publication date
- 12 January 2026